SlideShare a Scribd company logo
World Tuberculosis Day 2015
The TB situation in 2013: Findings from the joint
TB surveillance and monitoring report by
ECDC and the WHO Regional Office for Europe
ECDC TB Team
European Centre for Disease Prevention and Control
Stockholm, 24 March 2015
TB notifications by country
In 2013, 64 844 TB cases were reported in the EU/EEA.
The notification rate was 12.7 per 100 000 population (range 3.4–83.5).
2
Figure 1: TB
notification rate
per 100 000
population by
country, EU/EEA,
2013
Not included or not
reporting
20 to 49 per 100 000
10 to 19 per 100 000
5 to 9 per 100 000
< 5 per 100 000
≥ 50 per 100 000
TB notification rate over time
The TB notification rate has decreased from 19.3 per 100 000
population in 2004 to 12.7 in 2013.
3
Figure 2: TB notification rate per 100 000 population in EU/EEA
2004−2013
0
5
10
15
20
25
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
cases/100000
Year of reporting
EU definition: confirmed TB cases*
4
Figure 3:
Percentage of
laboratory-
confirmed TB
cases by country,
EU/EEA, 2013
70 to 79%
≥ 80%
60 to 69%
< 60%
Not included or
not reporting
* Confirmed by culture or by both a positive sputum microscopy result and Mycobacterium tuberculosis nucleic acid identified in
nucleic acid amplification test.
In 2013, 62.1% (range 21.4–94.3%) of TB cases reported
in the EU/EEA were laboratory confirmed.
Previously treated TB cases
5
In 2013, the proportion of all previously treated TB cases in
the EU/EEA was 11.7% (range 0.0–23.0%).
Figure 4:
Percentage of
previously
treated TB cases
by country,
EU/EEA, 2013
Not included or
not reporting
10 to 14.9%
≥ 15%
5 to 9.9%
< 5%
TB in children
6
Figure 5: TB
notification rate in
children under 15
years of age per
100 000 child
population, by
country, EU/EEA, 2013
Not included or not
reporting
4 to 9.9 per
100 000 child population
2 to 3.9 per
100 000 child population
≥ 10 per
100 000 child population
< 2 per
100 000 child population
In 2013, 2 655 TB cases in children were reported, accounting
for 4.1% of all notified TB cases (range 0–9.5%) in the EU/EEA.
TB cases of foreign origin
7
In 2013, the proportion of TB cases of foreign origin
in the EU/EEA was 28.0% (range 0.3–94.7%).
Figure 6:
Percentage of TB
cases of foreign
origin by country,
EU/EEA, 2013
25 to 49.9%
≥ 75%
1 to 24.9%
50 to 74.9%
< 1%
Not included or not
reporting
TB cases of foreign origin over time
The percentage of foreign TB cases increased from 18.2% in 2004
to 28.0% in 2013. The notification rate of foreign-origin TB cases
has remained stable since 2004 (between 3.4 and 3.8 per 100 000
population).
8
Figure 7: Percentage of TB cases with foreign origin, EU/EEA,
2004−2013
0
5
10
15
20
25
30
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Percentage
Year of reporting
Extrapulmonary TB cases
9
In 2013, the proportion of extrapulmonary TB cases
in the EU/EEA was 22.3% (range 4.7–63.6%).
Figure 8:
Percentage of
extrapulmonary
TB cases by
country, EU/EEA,
2013
20 to 29.9%
≥ 40%
10 to 19.9%
30 to 39.9%
< 10%
Not included or
not reporting
Multidrug-resistant TB among all TB cases
10
In 2013, the proportion of TB cases with multidrug-
resistance in the EU/EEA was 4.1% (range 0–22.7%).
Figure 9:
Percentage of
MDR TB among
all confirmed TB
cases by country,
EU/EEA, 2013
2 to 4.9%
≥ 10%
1 to 1.9%
5 to 9.9%
< 1%
Not included or
not reporting
Multidrug-resistant TB case notification
rate over time
The rate of notified MDR TB cases has remained stable over the past
five years at 0.3 per 100 000 population.
11
Figure 10: MDR TB notification rate per 100 000 population in EU/EEA
2009−2013
0.0
0.1
0.2
0.3
0.4
0.5
2009 2010 2011 2012 2013
cases/100000
Year of reporting
Multidrug-resistance among new
pulmonary TB cases
12
Figure 11:
Percentage of
new pulmonary
TB cases with
MDR TB by
country, EU/EEA,
2013
2 to 4.9%
1 to 1.9%
≥ 5%
< 1%
Not reporting
In 2013, the percentage of new pulmonary TB cases with multidrug-
resistance in the EU/EEA was 2.6% (range 0–17.3%).
Multidrug-resistance among previously
treated pulmonary TB cases
13
In 2013, the proportion of previously treated pulmonary TB cases with
multidrug-resistance in the EU/EEA was 17.0% (range 0–100.0%).
Figure 12:
Percentage of
previously treated
pulmonary TB
cases with MDR TB
by country,
EU/EEA, 2013
10 to 19.9%
≥ 20%
1 to 9.9%
< 1%
Not reporting
Extensively drug-resistant TB (XDR TB)
14
In 2013, the proportion of extensively drug-resistant TB cases among
multidrug-resistant cases in the EU/EEA was 17.5% (range 0–100.0%
and 4.2–36.4% for countries reporting more than one case).
Figure 13:
Percentage of XDR
TB cases among
MDR TB cases
tested for second-
line drug
susceptibility, by
country, EU/EEA,
2013
20 to 29.9%
10 to 19.9%
≥30%
< 10%
Not reporting
TB/HIV co-infection
15
In 2013, the proportion HIV positive among TB cases
with known HIV status in EU/EEA was 4.9% (range 0–22.6%).
Figure 14:
Percentage of HIV-
positive cases
among TB cases
with known HIV
status, by country,
EU/EEA, 2013
5 to 9.9%
1 to 4.9%
≥10%
< 1%
Not reporting
Treatment success after 12 months in all
TB cases*
The treatment success rate for all TB cases notified in 2012 was 73.5%
(range: 10.3–87.8%) and has remained stable over the past five years.
16
Figure 15: Treatment success rate of TB cases notified in 2012, by
country, EU/EEA, 2013
* Four EU/EEA Member States did not report treatment outcome data
0 20 40 60 80 100
EU/EEA
Croatia
Malta
Cyprus
Finland
Estonia
Ireland
Poland
Denmark
Austria
Lithuania
Hungary
Spain
Germany
Czech Republic
Belgium
Portugal
Latvia
Norway
United Kingdom
Romania
Sweden
Slovenia
Iceland
Netherlands
Bulgaria
Slovakia
Treatment success (%)
Treatment success in new confirmed
pulmonary TB cases and relapses started
on treatment in 2012*
The treatment success rate for confirmed new pulmonary TB cases and
relapses notified in 2012 was 77.1% (range: 9.3–90.0%).
17
Figure 16: Treatment success rate in confirmed new pulmonary TB cases and
relapses started on treatment in 2012, by country, EU/EEA, 2013
* Cases started on second line treatment are excluded
0 20 40 60 80 100
EU/EEA
Croatia
Malta
Cyprus
Finland
Poland
Ireland
Denmark
Spain
Hungary
Austria
Germany
Portugal
Czech Republic
Belgium
Norway
United Kingdom
Estonia
Sweden
Romania
Netherlands
Slovenia
Bulgaria
Latvia
Slovakia
Iceland
Treatment success (%)
Treatment success rate in
multidrug-resistant TB*
The treatment success rate for all multidrug-resistant TB cases notified in
2011 was 37.8% (range 0–75.0%).
18
Figure 17: 24-month treatment success rate in multidrug-resistant TB
cases notified in 2011, by country, EU/EEA, 2013
* Malta and Slovenia reported zero MDR TB cases in 2011, 9 Member States did not report treatment outcome data for MDR TB cases
0 20 40 60 80
EU/EEA
Denmark
Romania
Czech Republic
Ireland
Slovakia
Poland
Lithuania
Hungary
United Kingdom
Estonia
Portugal
Germany
Latvia
Bulgaria
Netherlands
Austria
Sweden
Belgium
Norway
Treatment success (%)
Treatment outcome in
multidrug-resistant TB over time
The treatment outcomes for multidrug-resistant TB cases improved slightly
between the 2009 and 2011 cohort, EU/EEA.
19
Figure 18: 24-month treatment outcome in multidrug-resistant TB cases
notified from 2009 to 2011, by year of initial case reporting, EU/EEA
0
10
20
30
40
Success Died Failed Defaulted or
unknown
Still on treatment
Treatmentoutcome(%)
MDR TB cohort 2009 MDR TB cohort 2010 MDR TB cohort 2011
20
Treatment success in
extensively drug-resistant TB*
The treatment success rate in extensively drug-resistant TB cases notified in
2010 was 25.9% (range 0–100.0%).
20
Figure 19: 36-month treatment success rate in extensively drug-resistant
TB cases notified in 2010, by country, EU/EEA, 2013
* Cyprus, Denmark, Italy, Norway, Slovakia and Slovenia reported zero XDR TB cases in 2010, 12 countries did not report SLD
DST results or XDR TB treatment outcome data
0
20
40
60
80
100
Treatmentsuccess(%)

More Related Content

What's hot (20)

PPT
Supporting the global vision of hepatitis B and C elimination - poster for IL...
European Centre for Disease Prevention and Control
 
PPTX
From Dublin to Rome: 10 years of the HIV epidemic and response in Europe
European Centre for Disease Prevention and Control
 
PDF
Screening Migrants at Europe’s Forefront: Migrant health and infectious disea...
European Centre for Disease Prevention and Control
 
PPTX
HIV AIDS Surveillance Report 2015
European Centre for Disease Prevention and Control
 
PDF
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
European Centre for Disease Prevention and Control
 
PPTX
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
European Centre for Disease Prevention and Control
 
PDF
Surveillance data on hepatitis B and C in EU/EEA 2014
European Centre for Disease Prevention and Control
 
PPTX
Recent epidemiology and outbreaks in Europe
European Centre for Disease Prevention and Control
 
PPTX
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
European Centre for Disease Prevention and Control
 
PPT
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
StopTb Italia
 
PPTX
HIV infection in children and adolescents in the EU/EEA 2015
European Centre for Disease Prevention and Control
 
PPTX
graphics trends for ecdc measles and rubella monitoring, 2013 2016
European Centre for Disease Prevention and Control
 
PPTX
World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015
European Centre for Disease Prevention and Control
 
PDF
What have we overlooked in the epidemiology of antimicrobial resistance in Eu...
European Centre for Disease Prevention and Control
 
PDF
Whole Genome Sequencing in EU Multi-country Foodborne Outbreak Investigation
European Centre for Disease Prevention and Control
 
PPTX
Tuberculosis situation in the EU/EEA, 2017
European Centre for Disease Prevention and Control
 
PDF
Tuberculosis situation in the EU/EEA, 2019
European Centre for Disease Prevention and Control
 
PPTX
Boost efforts to elimiate tuberculosis by 2050
WHO Regional Office for Europe
 
PPTX
Status of PrEP implementation in Europe (Nov 2019)
European Centre for Disease Prevention and Control
 
PDF
Monitoring the EU’s response to the HIV epidemic
European Centre for Disease Prevention and Control
 
Supporting the global vision of hepatitis B and C elimination - poster for IL...
European Centre for Disease Prevention and Control
 
From Dublin to Rome: 10 years of the HIV epidemic and response in Europe
European Centre for Disease Prevention and Control
 
Screening Migrants at Europe’s Forefront: Migrant health and infectious disea...
European Centre for Disease Prevention and Control
 
HIV AIDS Surveillance Report 2015
European Centre for Disease Prevention and Control
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
European Centre for Disease Prevention and Control
 
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
European Centre for Disease Prevention and Control
 
Surveillance data on hepatitis B and C in EU/EEA 2014
European Centre for Disease Prevention and Control
 
Recent epidemiology and outbreaks in Europe
European Centre for Disease Prevention and Control
 
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
European Centre for Disease Prevention and Control
 
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
StopTb Italia
 
HIV infection in children and adolescents in the EU/EEA 2015
European Centre for Disease Prevention and Control
 
graphics trends for ecdc measles and rubella monitoring, 2013 2016
European Centre for Disease Prevention and Control
 
World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015
European Centre for Disease Prevention and Control
 
What have we overlooked in the epidemiology of antimicrobial resistance in Eu...
European Centre for Disease Prevention and Control
 
Whole Genome Sequencing in EU Multi-country Foodborne Outbreak Investigation
European Centre for Disease Prevention and Control
 
Tuberculosis situation in the EU/EEA, 2017
European Centre for Disease Prevention and Control
 
Tuberculosis situation in the EU/EEA, 2019
European Centre for Disease Prevention and Control
 
Boost efforts to elimiate tuberculosis by 2050
WHO Regional Office for Europe
 
Status of PrEP implementation in Europe (Nov 2019)
European Centre for Disease Prevention and Control
 
Monitoring the EU’s response to the HIV epidemic
European Centre for Disease Prevention and Control
 

Similar to World Tuberculosis Day 2015: latest EU/EEA surveillance data (20)

PPTX
TB situation in the EU and EEA countries, 2014
European Centre for Disease Prevention and Control
 
PPTX
World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015
European Centre for Disease Prevention and Control
 
PPTX
Tuberculosis situation in the EU/EEA, 2018 - 2016 data
European Centre for Disease Prevention and Control
 
PDF
TB situation in 2011:Findings from the ECDC and WHO/EURO joint TB surveillanc...
StopTb Italia
 
PPTX
Tuberculosis situation in the EU/EEA, 2018
European Centre for Disease Prevention and Control
 
PPTX
TB DAY 2022 - Ritorno al futuro
Stop TB Italia Onlus
 
PDF
PPT Matteelli "Epidemiologia della TB"
StopTb Italia
 
PDF
Wtbd 2015 final_eng
WHO Regional Office for Europe
 
PPTX
World TB Day 2017 - presentation
WHO Regional Office for Europe
 
PPTX
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Meningitis Research Foundation
 
PPTX
Presentation - TB and HIV infection in the WHO European Region
WHO Regional Office for Europe
 
PDF
Basic concepts of tuberculosis
Ashraf ElAdawy
 
PDF
Risk factor analysis influenza
Cornelia Adlhoch
 
PDF
15 years of European AMR surveillance in perspective. Liselotte Diaz Högberg ...
European Centre for Disease Prevention and Control (ECDC)
 
PDF
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
European Centre for Disease Prevention and Control
 
PDF
Invasive meningococcal disease, Surveillance
European Centre for Disease Prevention and Control
 
PPT
6249919.ppt
Esam43
 
PDF
Congenital rubella still a public health problem in Italy: analysis of nation...
Cristobal Buñuel
 
PDF
Childhood multidrug-resistant tuberculosis (MDR-TB) in the EU/EEA: an analysi...
European Centre for Disease Prevention and Control
 
PPTX
Mealesss Global Regional MR Elimination Overview
LourduAnthoni1
 
TB situation in the EU and EEA countries, 2014
European Centre for Disease Prevention and Control
 
World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015
European Centre for Disease Prevention and Control
 
Tuberculosis situation in the EU/EEA, 2018 - 2016 data
European Centre for Disease Prevention and Control
 
TB situation in 2011:Findings from the ECDC and WHO/EURO joint TB surveillanc...
StopTb Italia
 
Tuberculosis situation in the EU/EEA, 2018
European Centre for Disease Prevention and Control
 
TB DAY 2022 - Ritorno al futuro
Stop TB Italia Onlus
 
PPT Matteelli "Epidemiologia della TB"
StopTb Italia
 
Wtbd 2015 final_eng
WHO Regional Office for Europe
 
World TB Day 2017 - presentation
WHO Regional Office for Europe
 
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Meningitis Research Foundation
 
Presentation - TB and HIV infection in the WHO European Region
WHO Regional Office for Europe
 
Basic concepts of tuberculosis
Ashraf ElAdawy
 
Risk factor analysis influenza
Cornelia Adlhoch
 
15 years of European AMR surveillance in perspective. Liselotte Diaz Högberg ...
European Centre for Disease Prevention and Control (ECDC)
 
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
European Centre for Disease Prevention and Control
 
Invasive meningococcal disease, Surveillance
European Centre for Disease Prevention and Control
 
6249919.ppt
Esam43
 
Congenital rubella still a public health problem in Italy: analysis of nation...
Cristobal Buñuel
 
Childhood multidrug-resistant tuberculosis (MDR-TB) in the EU/EEA: an analysi...
European Centre for Disease Prevention and Control
 
Mealesss Global Regional MR Elimination Overview
LourduAnthoni1
 
Ad

More from European Centre for Disease Prevention and Control (20)

PPTX
HIV AIDS surveillance in Europe 2019- 2018 data
European Centre for Disease Prevention and Control
 
PPTX
90-90-90 Goals in Europe: In Action
European Centre for Disease Prevention and Control
 
PDF
The public health response to increasing syphilis trends in Europe
European Centre for Disease Prevention and Control
 
PPTX
Situation overview on hepatitis E in the EU/EEA Member States
European Centre for Disease Prevention and Control
 
PPTX
Annual Epidemiological Report for 2017: Sexually Transmitted Diseases
European Centre for Disease Prevention and Control
 
PPTX
The attributable fraction of deaths due to viral hepatitis: results from a se...
European Centre for Disease Prevention and Control
 
PPTX
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
European Centre for Disease Prevention and Control
 
PDF
Online Respondent-Driven Detection (RDD)
European Centre for Disease Prevention and Control
 
PPTX
HIV/AIDS surveillance in Europe 2018 (2017 data)
European Centre for Disease Prevention and Control
 
PPTX
Infections among people who inject drugs -- problem solved?
European Centre for Disease Prevention and Control
 
PPTX
Strategies to reduce HIV incidence in Europe
European Centre for Disease Prevention and Control
 
PPTX
Sexually transmitted infections, EU/EEA, 2016
European Centre for Disease Prevention and Control
 
PPTX
Latest epidemiology on migrants in the European Union - ECDC
European Centre for Disease Prevention and Control
 
PDF
The use, and likelihood of using, HIV pre-exposure prophylaxis among men who ...
European Centre for Disease Prevention and Control
 
PPTX
Addressing the first 90: How can HIV testing more efficiently reach those in ...
European Centre for Disease Prevention and Control
 
PPTX
Addressing the second 90: How can treatment scale-up across the European regi...
European Centre for Disease Prevention and Control
 
PPTX
Addressing the third 90: Improving clinical outcomes and retention in care
European Centre for Disease Prevention and Control
 
PPTX
Overview of the HIV continuum of care in Europe and Central Asia, 2018
European Centre for Disease Prevention and Control
 
PPTX
Hepatitis B and C surveillance in the EU/EEA, 2016 data
European Centre for Disease Prevention and Control
 
HIV AIDS surveillance in Europe 2019- 2018 data
European Centre for Disease Prevention and Control
 
90-90-90 Goals in Europe: In Action
European Centre for Disease Prevention and Control
 
The public health response to increasing syphilis trends in Europe
European Centre for Disease Prevention and Control
 
Situation overview on hepatitis E in the EU/EEA Member States
European Centre for Disease Prevention and Control
 
Annual Epidemiological Report for 2017: Sexually Transmitted Diseases
European Centre for Disease Prevention and Control
 
The attributable fraction of deaths due to viral hepatitis: results from a se...
European Centre for Disease Prevention and Control
 
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
European Centre for Disease Prevention and Control
 
Online Respondent-Driven Detection (RDD)
European Centre for Disease Prevention and Control
 
HIV/AIDS surveillance in Europe 2018 (2017 data)
European Centre for Disease Prevention and Control
 
Infections among people who inject drugs -- problem solved?
European Centre for Disease Prevention and Control
 
Strategies to reduce HIV incidence in Europe
European Centre for Disease Prevention and Control
 
Sexually transmitted infections, EU/EEA, 2016
European Centre for Disease Prevention and Control
 
Latest epidemiology on migrants in the European Union - ECDC
European Centre for Disease Prevention and Control
 
The use, and likelihood of using, HIV pre-exposure prophylaxis among men who ...
European Centre for Disease Prevention and Control
 
Addressing the first 90: How can HIV testing more efficiently reach those in ...
European Centre for Disease Prevention and Control
 
Addressing the second 90: How can treatment scale-up across the European regi...
European Centre for Disease Prevention and Control
 
Addressing the third 90: Improving clinical outcomes and retention in care
European Centre for Disease Prevention and Control
 
Overview of the HIV continuum of care in Europe and Central Asia, 2018
European Centre for Disease Prevention and Control
 
Hepatitis B and C surveillance in the EU/EEA, 2016 data
European Centre for Disease Prevention and Control
 
Ad

Recently uploaded (20)

PPTX
Diabetes Mellitus - by Dr. Jessie Mlotha-Namarika, CHIEF DENTAL SURGEON, KAMU...
casumulupatrickcom
 
PPTX
Stroke Imaging: Fundamental principles and concepts
Dr. Aryan (Anish Dhakal)
 
PPTX
BASIC LIFE SUPPORT IN ADULTSby Majtania.pptx
Maj Tania Bose
 
PDF
Bassem Mourad Halim Matta
Smiling Lungs
 
PDF
MSTG 6th Edition Updated October 2024 CC.pdf
casumulupatrickcom
 
PPTX
Diabetes Mellitus ( Dharshini Pharm - D )
vetriselvan5666
 
PDF
Cardiovascular Physiology - Principles of Hemodynamics
MedicoseAcademics
 
PDF
Dermatology diseases Index July 2025.pdf
Hany salah Soliman
 
PPTX
Rotator cuff tears presentation ortho.pptx
sumitbhosale34
 
PPTX
Medico - legal issues in Surgical practice.pptx
DrPkumar5
 
PDF
Top-Rank Best Sexologist in Patna, Bihar India Different Age-Group SD Therapy...
Sexologist Dr. Sunil Dubey - Dubey Clinic
 
PPTX
POSTPARTUM HAEMORRHAGEby Maj Taniabose.pptx
Maj Tania Bose
 
PDF
BERITA TERBARU HOYE55 LOGIN LINK ALTERNARTIF SLOT88 GACOR 2025
hoye55
 
PPTX
Acute Pancreatitis and Lipotoxicity.pptx
Asmatullah Sapand MD PhD FRCP-UK
 
PPTX
Roganutpadaniya Adhyaya by Dr Harish M H- Consultant and Assistant professor ...
Dr Harish M Hadapad
 
PDF
Health-Care-Delivery-System-in-India.pdf
Rani ambrose
 
PPTX
Anatomy & Physiology of EAR and Physiology of Hearing
Prashant Ajmire
 
PPTX
Presentation on Ankylosing Spondylitis BY DR AVIJIT AND DR WAHED
DR AVIJIT DAS
 
PDF
CARDIAC LIFE SUPPORT - Jagadish N. BSN RN
Jagadish N. BSN RN
 
PPTX
X-RAY PHYSICS AND IT'S PROPERTIES & FUNDAMENTALS FOR RADIOLOGY ASPIRANTS.
Shubhambharti94
 
Diabetes Mellitus - by Dr. Jessie Mlotha-Namarika, CHIEF DENTAL SURGEON, KAMU...
casumulupatrickcom
 
Stroke Imaging: Fundamental principles and concepts
Dr. Aryan (Anish Dhakal)
 
BASIC LIFE SUPPORT IN ADULTSby Majtania.pptx
Maj Tania Bose
 
Bassem Mourad Halim Matta
Smiling Lungs
 
MSTG 6th Edition Updated October 2024 CC.pdf
casumulupatrickcom
 
Diabetes Mellitus ( Dharshini Pharm - D )
vetriselvan5666
 
Cardiovascular Physiology - Principles of Hemodynamics
MedicoseAcademics
 
Dermatology diseases Index July 2025.pdf
Hany salah Soliman
 
Rotator cuff tears presentation ortho.pptx
sumitbhosale34
 
Medico - legal issues in Surgical practice.pptx
DrPkumar5
 
Top-Rank Best Sexologist in Patna, Bihar India Different Age-Group SD Therapy...
Sexologist Dr. Sunil Dubey - Dubey Clinic
 
POSTPARTUM HAEMORRHAGEby Maj Taniabose.pptx
Maj Tania Bose
 
BERITA TERBARU HOYE55 LOGIN LINK ALTERNARTIF SLOT88 GACOR 2025
hoye55
 
Acute Pancreatitis and Lipotoxicity.pptx
Asmatullah Sapand MD PhD FRCP-UK
 
Roganutpadaniya Adhyaya by Dr Harish M H- Consultant and Assistant professor ...
Dr Harish M Hadapad
 
Health-Care-Delivery-System-in-India.pdf
Rani ambrose
 
Anatomy & Physiology of EAR and Physiology of Hearing
Prashant Ajmire
 
Presentation on Ankylosing Spondylitis BY DR AVIJIT AND DR WAHED
DR AVIJIT DAS
 
CARDIAC LIFE SUPPORT - Jagadish N. BSN RN
Jagadish N. BSN RN
 
X-RAY PHYSICS AND IT'S PROPERTIES & FUNDAMENTALS FOR RADIOLOGY ASPIRANTS.
Shubhambharti94
 

World Tuberculosis Day 2015: latest EU/EEA surveillance data

  • 1. World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office for Europe ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2015
  • 2. TB notifications by country In 2013, 64 844 TB cases were reported in the EU/EEA. The notification rate was 12.7 per 100 000 population (range 3.4–83.5). 2 Figure 1: TB notification rate per 100 000 population by country, EU/EEA, 2013 Not included or not reporting 20 to 49 per 100 000 10 to 19 per 100 000 5 to 9 per 100 000 < 5 per 100 000 ≥ 50 per 100 000
  • 3. TB notification rate over time The TB notification rate has decreased from 19.3 per 100 000 population in 2004 to 12.7 in 2013. 3 Figure 2: TB notification rate per 100 000 population in EU/EEA 2004−2013 0 5 10 15 20 25 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 cases/100000 Year of reporting
  • 4. EU definition: confirmed TB cases* 4 Figure 3: Percentage of laboratory- confirmed TB cases by country, EU/EEA, 2013 70 to 79% ≥ 80% 60 to 69% < 60% Not included or not reporting * Confirmed by culture or by both a positive sputum microscopy result and Mycobacterium tuberculosis nucleic acid identified in nucleic acid amplification test. In 2013, 62.1% (range 21.4–94.3%) of TB cases reported in the EU/EEA were laboratory confirmed.
  • 5. Previously treated TB cases 5 In 2013, the proportion of all previously treated TB cases in the EU/EEA was 11.7% (range 0.0–23.0%). Figure 4: Percentage of previously treated TB cases by country, EU/EEA, 2013 Not included or not reporting 10 to 14.9% ≥ 15% 5 to 9.9% < 5%
  • 6. TB in children 6 Figure 5: TB notification rate in children under 15 years of age per 100 000 child population, by country, EU/EEA, 2013 Not included or not reporting 4 to 9.9 per 100 000 child population 2 to 3.9 per 100 000 child population ≥ 10 per 100 000 child population < 2 per 100 000 child population In 2013, 2 655 TB cases in children were reported, accounting for 4.1% of all notified TB cases (range 0–9.5%) in the EU/EEA.
  • 7. TB cases of foreign origin 7 In 2013, the proportion of TB cases of foreign origin in the EU/EEA was 28.0% (range 0.3–94.7%). Figure 6: Percentage of TB cases of foreign origin by country, EU/EEA, 2013 25 to 49.9% ≥ 75% 1 to 24.9% 50 to 74.9% < 1% Not included or not reporting
  • 8. TB cases of foreign origin over time The percentage of foreign TB cases increased from 18.2% in 2004 to 28.0% in 2013. The notification rate of foreign-origin TB cases has remained stable since 2004 (between 3.4 and 3.8 per 100 000 population). 8 Figure 7: Percentage of TB cases with foreign origin, EU/EEA, 2004−2013 0 5 10 15 20 25 30 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Percentage Year of reporting
  • 9. Extrapulmonary TB cases 9 In 2013, the proportion of extrapulmonary TB cases in the EU/EEA was 22.3% (range 4.7–63.6%). Figure 8: Percentage of extrapulmonary TB cases by country, EU/EEA, 2013 20 to 29.9% ≥ 40% 10 to 19.9% 30 to 39.9% < 10% Not included or not reporting
  • 10. Multidrug-resistant TB among all TB cases 10 In 2013, the proportion of TB cases with multidrug- resistance in the EU/EEA was 4.1% (range 0–22.7%). Figure 9: Percentage of MDR TB among all confirmed TB cases by country, EU/EEA, 2013 2 to 4.9% ≥ 10% 1 to 1.9% 5 to 9.9% < 1% Not included or not reporting
  • 11. Multidrug-resistant TB case notification rate over time The rate of notified MDR TB cases has remained stable over the past five years at 0.3 per 100 000 population. 11 Figure 10: MDR TB notification rate per 100 000 population in EU/EEA 2009−2013 0.0 0.1 0.2 0.3 0.4 0.5 2009 2010 2011 2012 2013 cases/100000 Year of reporting
  • 12. Multidrug-resistance among new pulmonary TB cases 12 Figure 11: Percentage of new pulmonary TB cases with MDR TB by country, EU/EEA, 2013 2 to 4.9% 1 to 1.9% ≥ 5% < 1% Not reporting In 2013, the percentage of new pulmonary TB cases with multidrug- resistance in the EU/EEA was 2.6% (range 0–17.3%).
  • 13. Multidrug-resistance among previously treated pulmonary TB cases 13 In 2013, the proportion of previously treated pulmonary TB cases with multidrug-resistance in the EU/EEA was 17.0% (range 0–100.0%). Figure 12: Percentage of previously treated pulmonary TB cases with MDR TB by country, EU/EEA, 2013 10 to 19.9% ≥ 20% 1 to 9.9% < 1% Not reporting
  • 14. Extensively drug-resistant TB (XDR TB) 14 In 2013, the proportion of extensively drug-resistant TB cases among multidrug-resistant cases in the EU/EEA was 17.5% (range 0–100.0% and 4.2–36.4% for countries reporting more than one case). Figure 13: Percentage of XDR TB cases among MDR TB cases tested for second- line drug susceptibility, by country, EU/EEA, 2013 20 to 29.9% 10 to 19.9% ≥30% < 10% Not reporting
  • 15. TB/HIV co-infection 15 In 2013, the proportion HIV positive among TB cases with known HIV status in EU/EEA was 4.9% (range 0–22.6%). Figure 14: Percentage of HIV- positive cases among TB cases with known HIV status, by country, EU/EEA, 2013 5 to 9.9% 1 to 4.9% ≥10% < 1% Not reporting
  • 16. Treatment success after 12 months in all TB cases* The treatment success rate for all TB cases notified in 2012 was 73.5% (range: 10.3–87.8%) and has remained stable over the past five years. 16 Figure 15: Treatment success rate of TB cases notified in 2012, by country, EU/EEA, 2013 * Four EU/EEA Member States did not report treatment outcome data 0 20 40 60 80 100 EU/EEA Croatia Malta Cyprus Finland Estonia Ireland Poland Denmark Austria Lithuania Hungary Spain Germany Czech Republic Belgium Portugal Latvia Norway United Kingdom Romania Sweden Slovenia Iceland Netherlands Bulgaria Slovakia Treatment success (%)
  • 17. Treatment success in new confirmed pulmonary TB cases and relapses started on treatment in 2012* The treatment success rate for confirmed new pulmonary TB cases and relapses notified in 2012 was 77.1% (range: 9.3–90.0%). 17 Figure 16: Treatment success rate in confirmed new pulmonary TB cases and relapses started on treatment in 2012, by country, EU/EEA, 2013 * Cases started on second line treatment are excluded 0 20 40 60 80 100 EU/EEA Croatia Malta Cyprus Finland Poland Ireland Denmark Spain Hungary Austria Germany Portugal Czech Republic Belgium Norway United Kingdom Estonia Sweden Romania Netherlands Slovenia Bulgaria Latvia Slovakia Iceland Treatment success (%)
  • 18. Treatment success rate in multidrug-resistant TB* The treatment success rate for all multidrug-resistant TB cases notified in 2011 was 37.8% (range 0–75.0%). 18 Figure 17: 24-month treatment success rate in multidrug-resistant TB cases notified in 2011, by country, EU/EEA, 2013 * Malta and Slovenia reported zero MDR TB cases in 2011, 9 Member States did not report treatment outcome data for MDR TB cases 0 20 40 60 80 EU/EEA Denmark Romania Czech Republic Ireland Slovakia Poland Lithuania Hungary United Kingdom Estonia Portugal Germany Latvia Bulgaria Netherlands Austria Sweden Belgium Norway Treatment success (%)
  • 19. Treatment outcome in multidrug-resistant TB over time The treatment outcomes for multidrug-resistant TB cases improved slightly between the 2009 and 2011 cohort, EU/EEA. 19 Figure 18: 24-month treatment outcome in multidrug-resistant TB cases notified from 2009 to 2011, by year of initial case reporting, EU/EEA 0 10 20 30 40 Success Died Failed Defaulted or unknown Still on treatment Treatmentoutcome(%) MDR TB cohort 2009 MDR TB cohort 2010 MDR TB cohort 2011
  • 20. 20 Treatment success in extensively drug-resistant TB* The treatment success rate in extensively drug-resistant TB cases notified in 2010 was 25.9% (range 0–100.0%). 20 Figure 19: 36-month treatment success rate in extensively drug-resistant TB cases notified in 2010, by country, EU/EEA, 2013 * Cyprus, Denmark, Italy, Norway, Slovakia and Slovenia reported zero XDR TB cases in 2010, 12 countries did not report SLD DST results or XDR TB treatment outcome data 0 20 40 60 80 100 Treatmentsuccess(%)